YD Bio Limited YDES 深 滬
等待開盤 07-25 09:30:00 美东时间
2.24
+0.200
+9.80%
華盛通- 最 高2.44
- 今 開2.44
- 成交量 8.31万股
- 最 低 1.96
- 昨 收 2.04
- 總市值 1.59亿
- 52周最高 25.00
- 市盈率 靜 --
- 換手率 0.12%
- 52周最低 1.70
- 委 比 -77.42%
- 總股本 7083.13万
- 歷史最高 25.00
- 量 比 3.14
- 振 幅 23.53%
- 歷史最低 1.70
- 每 手 1
- 風險率 5.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | IREN升逾13%！此前获Anthropic数据中心候选资格；高性能计算公司SHAZ涨近18%
IREN升逾13%！获Anthropic数据中心候选资格；商业媒体公司CRTO升逾21%，获溢价50%收购要约；高性能计算公司SHAZ涨近18%，此前完成16亿美元重磅战略融资>>
07-07 19:04
YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations
YD Bio Limited announced that its affiliate, EG BioMed US Inc., has obtained clinical laboratory licenses in Rhode Island and Pennsylvania, expanding its CLIA-certified, CAP-accredited laboratory's reach to 46 U.S. states. This expansion enhances patient access to blood-based cancer detection services and supports the Company's transition to a platform-based biotechnology company focused on real-world molecular data. The laboratory's growth is se...
07-02 12:00
Autoliv Posts Upbeat Q1 Results, Joins United Airlines, Royal Caribbean Cruises And Other Big Stocks Moving Higher On Friday
The Dow Jones index rose 700 points, Autoliv Inc (NYSE: ALV) reported strong results causing a jump in its shares by 8.4% to $120.77. Other big gainers included CRML, ABTC, MFI, BYND, RXT, SHMD, MGRT, CWH, CRVS, ALK, YDES.
04-17 22:09
YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States
Taiwanese biotechnology company YD Bio, in collaboration with EG BioMed, has launched the EG Telehealth Platform, marking a significant step in commercializing early cancer detection and clinical services across the U.S. The platform, accessible in 44 states, D.C., and Guam, integrates YD Bio's digital health solutions with EG BioMed's certified diagnostic capabilities, enabling scalable deployment and nationwide patient access. Designed for dece...
03-31 12:00
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers ENvue Medical (NASDAQ:FEED) shares increased by 59.4% to $2.28 during T...
03-25 01:05
Apogee Therapeutics, Tower Semiconductor, Norwegian Cruise Line And Other Big Stocks Moving Higher On Thursday
Stocks fall, Nasdaq drops 200 points. Apogee Therapeutics (APGE) rises 19.4% on positive trial data. Satellogic (SATL), YD Bio (YDES), AXT Inc (AXTI) also see gains.
03-23 22:45
YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem
Taipei, Taiwan, March 17, 2026 (GLOBE NEWSWIRE) - YD Bio Limited, a biotech company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, has outlined its strategic roadmap under CEO Dr. Ethan Shen. The company is moving beyond the traditional single-asset biotech model to build an integrated healthcare ecosystem, synchronizing diagnostic intelligence with advanced therapeutic execution. Key highlights includ...
03-17 12:00
YD Bio's Subsidiary Enters Into Master Strategic Alliance Agreement With YC Biotech To Establish Taiwan-U.S. Dual-Core Regulatory Platform
YD Bio Limited ("YD Bio Ltd" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that its subsidiary YD Bio
02-25 21:10
YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy
YD Bio Ltd entered into a definitive Letter of Intent to acquire Safe Save Medical Cell Sciences & Technology Co., Ltd. (SSMC) for approximately US$26.87 million, combining cash and new shares. SSMC specializes in dendritic cell immunotherapy with its ADCTA technology. The acquisition aims to augment YD Bio's R&D capabilities and expand its presence in cell and gene therapies. The deal, subject to customary closing conditions, is expected to clos...
01-29 13:30
YD Bio Strikes Memorandum Of Understanding To Merge With EG BioMed; Financial Terms Not Disclosed
YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company has entered
01-06 22:09
